GSK stock reports Q2 sales growth despite profit hit

Published on 10/05/2026 at 20:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock was last at GBp 1,772.00 on October 5, 2026, as Q2 turnover rose 5 percent. Total operating profit fell 76 percent to GBP 481 million.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) was last at GBp 1,772.00 on the London Stock Exchange on October 5, 2026, down 0.42 percent at 8:10 a.m. London time. The company enters its next reporting checkpoint with Q2 turnover up 5 percent, but impairment charges pushed total operating profit sharply lower.

Q2 sales grow as profit falls

According to StockTitan on September 8, 2026, GSK reported Q2 2026 turnover of GBP 8.409 billion for the quarter ended June 30, 2026, up 5 percent at both actual exchange rates and constant exchange rates from Q2 2025.

The operating picture was more difficult. Total operating profit fell 76 percent to GBP 481 million, while total earnings per share declined 69 percent to GBp 10.8. The same filing attributed the pressure mainly to a GBP 1.33 billion impairment linked to camlipixant and a GBP 371 million charge related to terminated Alector assets.

Specialty medicines carry growth

GSK's business mix explains why sales growth and reported profit moved in opposite directions. Specialty Medicines revenue increased 14 percent to GBP 3.78 billion in Q2 2026, and Vaccines revenue rose 9 percent to GBP 2.28 billion, while General Medicines declined 9 percent to GBP 2.34 billion, according to StockTitan.

Core operating profit increased 6 percent to GBP 2.800 billion, and core earnings per share rose to GBp 50.5 from GBp 46.5 in Q2 2025. That contrast makes adjusted operating performance the key measure for the next update, while the impairment charges remain a direct drag on reported earnings.

Analysts see 16.5 percent upside

According to MarketBeat on September 30, 2026, eight analysts held a consensus rating of Hold, with five Hold ratings, two Buys and one Sell. Their average 12-month target was GBp 2,064.38, placing the October 5 price 14.2 percent below that target.

Berenberg raised its GSK target from GBp 2,000 to GBp 2,200 on September 15, 2026, while retaining a Hold rating, according to MarketBeat. The target change contrasts with the broader Hold consensus and leaves the pipeline and the financial impact of development setbacks as the central valuation questions.

GSK stock stays below its yearly high

GSK stock was last at GBp 1,772.00 on the LSE on October 5, 2026, with a session range of GBp 1,772.00 to GBp 1,788.00 and volume of 108,150 shares. The 52-week range was GBp 1,592.00 to GBp 2,282.00, placing the price 22.3 percent below the yearly high.